REMSleep Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Marshall
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2202 North West Shore Boulevard Tampa FL United States of America 33607
- IPO Date
- Jul 24, 2009
- CIK
- 0001412126
- Website
- remsleeptech.com
- Similar Companies
- Business
- REMSleep Holdings, Inc. is a medical device manufacturer specializing in the design and production of devices and products for the treatment of obstructive sleep apnea and other respiratory conditions. Its core product offerings include CPAP machines sold under the ResPlus brand and the recently launched DeltaWave CPAP Mask System, a patented, FDA-cleared nasal pillows interface designed to improve patient comfort and compliance by providing maximum airflow with minimal noise and facial strain. The company operates primarily in the United States, with its headquarters located in Clearwater, Florida. Founded in 2015, REMSleep leverages over 30 years of collective experience in CPAP therapy within its team to address challenges in sleep apnea treatment. In recent developments, REMSleep has entered into a formal marketing and distribution agreement with 1800CPAP.com, a major durable medical equipment (DME) distributor, facilitating nationwide availability of the DeltaWave CPAP mask. The company has also secured Medicare registration approval for its products, expanding insurance coverage for patients. Strategic initiatives include a partnership with former VP of Marketing John Stelzner to lead brand development and marketing efforts, including national media campaigns, outreach to Veterans Affairs (VA) and DME providers, distributor partnerships, and planned clinical trials. Operational adjustments have included relocating to a less expensive lease facility and a significant reduction in research and development expenses after the completion of DeltaWave product development and testing. REMSleep aims to capture a 10% market share in the CPAP mask sector within the next 24 months, targeting a growing market valued at over $600 million with projections to exceed $1 billion by 2033. The company is in the health care equipment industry segment, focusing on sleep disorder treatment devices, and its strategic focus remains on expanding its product reach through enhanced marketing, clinical validation, and broadening distribution channels to improve patient compliance and outcomes in sleep apnea therapy. REMSleep Holdings is listed on the OTC Pink under the ticker RMSL.
Deltawave(TM) Launch Plan
Deltawave CPAP Mask
REMSleep Enters Formal Agreement with Major Distributor
REMSleep Holdings, Inc. Shareholder Update
REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office
REMSleep Holdings Inc. Issues Shareholder Letter
REMSleep Holdings Inc. Issues Shareholder Letter
REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples
REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples
REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System
REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System
REMSleep Holdings Inc. Receives 510(K) Clearance on Product
REMSleep Holdings Inc. Receives 510(K) Clearance on Product
REMSleep Holdings Patent Status
REMSleep Holdings Shareholder Update
Remsleep Holdings Inc.'s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)
Remsleep Holdings Inc.'s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)
Remsleep Holdings Inc.'s DeltaWave Mask Moves to Substantive Review of FDA 510k Process
RemSleep Holdings Inc. Announces Submission of DeltaWave Mask for FDA 510K Review
RemSleep Holdings Inc. Provides an Update on Funding and DeltaWave